Therapeutics for a better life.
Therapeutics for a better life
Welcome to Red Leaf Medical
Red Leaf Medical (RLM) is a leading Canadian healthcare company specializing in urology and infectious disease. The Company provides innovative therapies and solutions in the areas of pelvic floor health, fertility and urinary tract infections. Red Leaf Medical is a trusted partner to patients and healthcare providers offering industry leading services and patient support programs.
New Vaccine Reduces Recurrent Urinary Tract Infections in Women
Results from the first North American Clinical Experience Study provides further evidence of MV140 safety and efficacy. Red Leaf Medical (RLM) announced that results from the first North American clinical evidence for MV 140, a sublingual vaccine for the prevention of recurrent urinary tract infections (rUTI) in women, were published in the Canadian Urological Association Journal (February 2024).
MV140 Vaccine for Recurrent Urinary Tract Infections in the News
The Globe and Mail and CTV News recently published reports indicating that MV140, Red Leaf Medical’s sublingual vaccine for the prevention of recurrent urinary tract infections in women, is awaiting Health Canada approval. The news items explain the impact of UTIs on women’s health and how the antibiotics used to treat them are contributing to antimicrobial resistance. Read the online CTV story here and watch the video of the story that aired on their broadcast here. The Globe and Mail article was published on February 27, 2023.
Red Leaf Medical Files for Approval of UROMUNE™ in Canada
Red Leaf Medical has filed a new drug submission with Health Canada for approval of UROMUNE™, a sublingual vaccine for the prevention of recurrent urinary tract infections(rUTIs) in women. The new drug submission is supported by results from a UROMUNE™ multicenter, prospective, randomized, double-blind, placebo-controlled trial. These results were recently published in the New England Journal of Medicine Evidence.
Uromune™ Multicentre Study Published In NEJM Evidence
Red Leaf Medical is pleased to announce that results from a multicenter randomized placebo-controlled trial of UROMUNE™, a sublingual vaccine for the prevention of recurrent urinary tract infections in women, were published online in the New England Journal of Medicine Evidence. Data indicates that the new vaccine significantly decreases urinary tract infections and prevents recurrence in women.
CathetersPLUS™ is a division of Red Leaf Medical that is committed to improving the lives of patients who use catheters. Our catheter specialists are available to assist catheter users across Canada by providing exceptional patient support.
ConceptionPLUS™ is a division of Red Leaf Medical that provides patient information about the causes of male infertility and offers access to potential solutions, such as PROfortil®. PROfortil® is a natural health product approved by Health Canada for male fertility disorders.
RLM is a member of CAIC and supports their mandate to protect the Canadian population from the rise in antimicrobial resistance, by positioning Canada to be a leader in AMR research and product development, economic growth, and investment.